Paraneoplastic neurological syndromes: Unusual presentations of cancer. A practical review

American Journal of the Medical Sciences

Volumn 340, Issue 4, 2010, Pages 301-308

  Braik, Tareq ^a   Evans, Arthur T ^b   Telfer, Margaret ^b   McDunn, Susan ^b  

^a Jr Hospital of Cook County   (United States)

^b NONE

Author keywords

Autoantibodies; Neoplasm; Nervous system; Paraneoplastic

Indexed keywords

3,4 DIAMINOPYRIDINE; AUTOANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB; STEROID; TACROLIMUS;

CANCER INCIDENCE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; EATON LAMBERT SYNDROME; ENCEPHALOMYELITIS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPSOCLONUS MYOCLONUS SYNDROME; PARANEOPLASTIC ENCEPHALOMYELITIS; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC SYNDROME; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMAPHERESIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; SUBACUTE SENSORY NEURONOPATHY;

EID: 77958007590     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181d9bb3b     Document Type: Review

References (66)

1. Graus F, Dalmau J. Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol 2007;20:732-737
2. Nath U, Grant R. Neurological paraneoplastic syndromes. J Clin Pathol 1997;50:975-980
3. Bataller L, Dalmau J. Paraneoplastic neurologic syndromes. Neurol Clin 2003;21:221-247
4. Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol 1999; 9:275-284
5. Dalmau J, Graus F, Rosenblum MK, et al. Anti-Hu associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine (Baltimore) 1992;71:59-72.
6. Linke R, Schroeder M, Helmberger T, et al. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 2004;63:282-286
7. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008;7:327-340
8. Graus F, Keime-Guibert F, Reñe R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124: 1138-1148
9. Younes-Mhenni S, Janier MF, Cinotti L, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004;127:2331-2338
10. Mathew RM, Vandenberghe R, Garcia-Merino A, et al. Orchiectomy for suspected microscopic tumor in patients with anti-Ma2- associated encephalitis. Neurology 2007;68:900-905
11. Vega F, Graus F, Chen QM, et al. Intrathecal synthesis of the anti-Hu antibody in patients with paraneoplastic encephalomyelitis or sensory neuronopathy: clinical-immunologic correlation. Neurology 1994;44: 145-147
12. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000;123:1481-1494
13. Lawn ND, Westmoreland BF, Kiely MJ, et al. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc 2003;78:1363-1368
14. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75:1135-1140
15. Inuzuka T. Autoantibodies in paraneoplastic neurological syndrome. Am J Med Sci 2000;319:217-226
16. Voltz R. Can antibodies in serum predict the presence of microscopic tumors? Neurology 2007;68:887-888
17. Dalmau J, Posner JB. Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity. Neurology 1994;44:2241-2246
18. Minisini AM, Pauletto G, Bergonzi P, et al. Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature. Breast Cancer Res Treat 2007;105:133-138
19. Sillevis-Smitt P, Manley G, Moll JW, et al. Pitfalls in the diagnosis of autoantibodies associated with paraneoplastic neurologic disease. Neurology 1996;46:1739-1741
20. Llado A, Mannucci P, Carpentier AF, et al. Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes. Neurology 2004;63:1947-1949
21. Amato AA, Collins MP. Neuropathies associated with malignancy. Semin Neurol 1998;18:125-144
22. Croft PB, Wilkinson M. The incidence of carcinomatous neuromyopathy in patients with various types of carcinoma. Brain 1965;88: 427-434
23. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998;50:652-657
24. Voltz R, Gultekin SH, Rosenfeld MR, et al. A serological marker of paraneoplastic limbic and brainstem encephalitis in patients with testicular cancer. N Engl J Med 1999;340:1788-1795
25. Hernández-Echebarría L, Saiz A, Arés A, et al. Graus F: Paraneoplastic encephalomyelitis associated with pancreatic tumor and anti- GAD antibodies. Neurology 2006;66:450-451
26. Coeytaux A, Kressig R, Zulian GB. Hepatocarcinoma with concomitant paraneoplastic encephalomyelitis. J Palliat Care 2001;17:59-60.
27. Wilkinson PC, Zeromski J. Immunofluorescent detection of antibodies against neurones in sensory carcinomatous neuropathy. Brain 1965; 88:529-583
28. Molinuevo JL, Graus F, Serrano C, et al. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 1998;44:976-980
29. Dalmau J, Furneaux HM, Cordon-Cardo C, et al. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol 1992;141:881-886
30. Denny-Brown D. Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiatry 1948;11:73-87.
31. Voltz RD, Posner JB, Dalmau J, et al. Paraneoplastic encephalomyelitis: an update of the effects of the anti-Hu immune response on the nervous system and tumour. J Neurol Neurosurg Psychiatry 1997;63: 133-136
32. Shavit YB, Graus F, Probst A, et al. Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol 1999;45:255-258
33. Tojo K, Tokuda T, Yazaki M, et al. Paraneoplastic sensorimotor neuropathy and encephalopathy associated with anti-alpha-enolase antibody in a case of gastric adenocarcinoma. Eur Neurol 2004;51:231-233
34. Dropcho EJ. Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol 1996;39: 659-667
35. Honnorat J, Aguera M, Zalc B, et al. POP66, a paraneoplastic encephalomyelitis related antigen, is a marker of adult oligodendrocytes. J Neuropathol Exp Neurol 1998;57:311-322
36. Kort DH, Vallerie AM, DeMarco EF, et al. Paraneoplastic anti-Nmethyl- d-aspartate-receptor encephalitis from mature cystic teratoma. Obstet Gynecol 2009;114:373-376
37. Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-Daspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25-36. (Pubitemid 46214241)
38. Seki M, Suzuki S, Dalamu J, et al. Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis. J Neurol Neurosurg Psychiatry 2008;79:324-326
39. Iizuka T, Hara A. Anti-NMDA receptor antibody-mediated encephalitis/ encephalopathy. Rinsho Byori 2009;57:252-261
40. Suzuki S, Seki M, Suzuki N. Anti-NMDAR encephalopathy: treatment. Rinsho Shinkeigaku 2008;48:923-925
41. Batson OA, Fantle DM, Stewart JA. Paraneoplastic encephalomyelitis: dramatic response to chemotherapy alone. Cancer 1992;69:1291-1293
42. Keime-Guibert F, Graus F, Broët P, et al. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology 1999;53:1719-1723
43. Graus F, Vega F, Delattre JY, et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes and antineuronal autoantibodies. Neurology 1992;42:536-540
44. Tuzun E, Dalmau J. Limbic encephalitis and variants: Classification, diagnosis and treatment. Neurologist 2007;13:261-271 (Pubitemid 47396312)
45. De Andres C, Esquivel A, de Villoria JG, et al. Unusual magnetic resonance imaging and cerebrospinal fluid findings in paraneoplastic cerebellar degeneration: a sequential study. J Neurol Neurosurg Psychiatry 2006;77:562-563
46. Giometto B, Marchiori GC, Nicolao P, et al. Sub-acute cerebellar degeneration with anti-Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol 1997;23:468-474
47. Verschuuren J, Chuang L, Rosenblum MK, et al. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol (Berl) 1996; 91:519-525
48. Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000;55:713-715
49. Bernal F, Shamsili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003;60:230-234
50. Esposito M, Penza P, Orefice G, et al. Successful treatment of paraneoplastic cerebellar degeneration with Rituximab. J Neurooncol 2008;86:363-364
51. Cocconi G, Ceci G, Juvarra G, et al. Successful treatment of subacute cerebellar degeneration in ovarian carcinoma with plasmapheresis. A case report. Cancer 1985;56:2318-2320
52. Widdess-Walsh P, Tavee JO, Schuele S, et al. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol 2003;63:187-190
53. Phuphanich S, Brock C. Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody. J Neurooncol 2008;81:67-69
54. Wong AM, Musallam S, Tomlinson RD, et al. Opsoclonus in three dimensions: oculographic, neuropathologic and modelling correlates. J Neurol Sci 2001;189:71-81.
55. Pranzatelli MR. The immunopharmacology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 1996;19:1-47.
56. Bataller L, Rosenfeld MR, Graus F, et al. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 2003;53:347-353
57. Luque FA, Furneaux HM, Ferziger R. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991;29:241-251
58. Connolly AM, Pestronk AS, Mehta MR, et al. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. J Pediatr 1997;130:878-884
59. Bataller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001;124: 437-443
60. Erlich R, Morrison C, Kim B, et al. ANNA-2: an antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features-correlation of clinical improvement with tumor response. Cancer Invest 2004;22:257-261
61. Camdessanche JP, Antoine JC, Honnorat J, et al. Paraneoplastic peripheral neuropathy associated with anti-hu antibodies. A clinical and electrophysiological study of 20 patients. Brain 2002;125:166-175
62. Thomas BT, Rubin M. Paraneoplastic neurological syndromes: a review. Neurologist 2009;15:21-33.
63. Lennon VA. Serological profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome. Neurology 1997;48: 523-527
64. Sanders DB. Lambert-Eaton myasthenic syndrome, diagnosis and treatment. Ann NY Acad Sci 2003;998:500-508
65. Sanders DB, Massey JM, Sanders LL, et al. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000;54:603-607
66. Chalk CH, Murray N, Newsome-Davis J, et al. Response of Lambert- Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990;40:1552-1556